A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects with DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated with Ruxolitinib (The FREEDOM trial)
An Efficacy and Safety Trial of Fedratinib in Subjects With Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)
Sponsor: Celgene-Impact
Enrolling: Male and Female Patients
IRB Number: AAAS3031
U.S. Govt. ID: NCT03755518
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: You are being asked to take part in this study because you have been diagnosed with Myeloproliferative neoplasm (MPN) Associated Myelofibrosis (your disease) and have received ruxolitinib. The purpose of this study is to confirm how well this study treatment works to reduce your spleen volume, spleen size, what effect the study treatment has on you and your disease and what effect has on your quality of life. We are conducting this clinical research study of an investigational drug called fedratinib. Fedratinib is being investigated for the treatment of MPN-associated myelofibrosis in patients previously treated with ruxolitinib.
This study is closed
Mark Heaney, MD, PhD
Do You Qualify?
Are you at least 18 years of age? Yes No
Do you have primary myelofibrosis, post-Essential Thrombocythemia Myelofibrosis, or post-Plycythemia Vera Myelofibrosis? Yes No
Have you been previously treated with Ruxolitinib? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator